Finch Therapeutics Group, Inc. (FNCH) OTC

12.13

-0.1364(-1.11%)

Updated at October 03 03:50PM

Currency In USD

Finch Therapeutics Group, Inc.

Address

200 Inner Belt Road

Somerville, MA 02143

United States of America

Phone

617 229 6499

Sector

Healthcare

Industry

Biotechnology

Employees

1

First IPO Date

March 19, 2021

Key Executives

NameTitlePayYear Born
Mr. Matthew P. Blischak J.D.President, Secretary & Chief Executive Officer558,8071963
Mr. James S. Sigler MBAExecutive Vice President of CMC01961

Description

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.